This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
Mitra rezaei
Shahid Beheshti University of Medical Sciences School of Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0729-5222
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Various studies showed the usage of epidermal growth factor receptors (EGFRs) gene mutations in the therapeutic plan of patients with advanced lung cancer. This study aimed to investigate the frequency and types of EGFR gene mutations among Iranian patients with lung cancer referred to a specialized lung diseases hospital from 2014 to 2019.
Results
The study was included 570 individuals, with an average age of 58.74 years old, of which 51.6% were men and 48.4% were women. Gene mutations were present in 113 of the 570 (19.8%) participants. There was deletion, replacement, and deletion and replacement in 65 (57%), 48 (42.1%), and (0.9%) cases, respectively. The mutation was significantly higher among women (P = 0.001); in detail, deletion was higher among female participants, although the replacement mutation was the same in male and female groups. There were no significant differences in mutation among different age groups (P = 0.05).
Conclusion
EGFR gene mutations, associated with lung cancer and could help patients' therapeutic plan, had the frequency of about 19.8% among Iranian patients with lung cancer.
Keywords
EGFR Mutation, Lung cancer, Frequency, Deletion, Replacement
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 29 Apr, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Mitra rezaei
Shahid Beheshti University of Medical Sciences School of Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0729-5222
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 29 Apr, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Various studies showed the usage of epidermal growth factor receptors (EGFRs) gene mutations in the therapeutic plan of patients with advanced lung cancer. This study aimed to investigate the frequency and types of EGFR gene mutations among Iranian patients with lung cancer referred to a specialized lung diseases hospital from 2014 to 2019.
Results
The study was included 570 individuals, with an average age of 58.74 years old, of which 51.6% were men and 48.4% were women. Gene mutations were present in 113 of the 570 (19.8%) participants. There was deletion, replacement, and deletion and replacement in 65 (57%), 48 (42.1%), and (0.9%) cases, respectively. The mutation was significantly higher among women (P = 0.001); in detail, deletion was higher among female participants, although the replacement mutation was the same in male and female groups. There were no significant differences in mutation among different age groups (P = 0.05).
Conclusion
EGFR gene mutations, associated with lung cancer and could help patients' therapeutic plan, had the frequency of about 19.8% among Iranian patients with lung cancer.
Figure 1
Loading...